Proceedings · Session S-820 · filed November 17, 2026

Lab Technology & MethodsSession paper

Cornell and USDA Platform Lifts Cannabis Genotyping Efficiency to 88.5%

CannSelect, a Cornell-USDA genotyping platform, raised targeted sequence capture from 35.8% to 88.5% and confirmed an autoflowering gene region in 321 plants.

By Rebecca Stone3 min read669 words

Summary

  • Cornell and USDA researchers published the CannSelect platform in PLOS One on November 11.
  • The platform's average capture efficiency for targeted genetic sequences rose from 35.8% to 88.5% after design improvements.
  • Validation used 321 plants from two breeding populations and pinpointed a chromosome 1 region linked to autoflowering.
  • Funding came from the Foundation for Food and Agriculture Research and the New York State Department of Agriculture and Markets.
  • The platform's genetic data and design code are publicly available.
USDA and University Researchers Develop New Genetic Testing Platform for Cannabis Breeding
FigureUSDA and University Researchers Develop New Genetic Testing Platform for Cannabis Breeding — Mahmoud-Ahmed / pixabay

A new genetic testing platform developed by Cornell University and the U.S. Department of Agriculture raised its average capture rate of targeted gene sequences from 35.8% to 88.5%, according to a study published November 11 in the journal PLOS One. The platform, named CannSelect, is designed to help cannabis breeders identify plants carrying commercially useful traits without sequencing the entire genome.

The work matters for breeding programs on two fronts: cost and precision. Cannabis genomes are large and highly repetitive, which makes whole-genome sequencing expensive at the scale a breeding program needs. CannSelect instead uses targeted genotyping — a method that reads only pre-selected regions of the genome — to examine genetic variation at genes linked to traits breeders actually select for.

What traits does the platform target?

According to the study, CannSelect focuses on genes associated with:

  • disease resistance
  • environmental stress tolerance
  • flowering time
  • plant size
  • trichome density (the small resin glands on flowers that produce cannabinoids)
  • cannabinoid production

That list maps directly onto the decisions a breeding operation makes each cycle: which seedlings to keep, which lines to cross, and which cultivars can survive outdoor field conditions or greenhouse schedules.

How was it validated?

The researchers tested the platform on 321 plants drawn from two cannabis breeding populations. In that sample, CannSelect successfully pinpointed a previously identified region of chromosome 1 associated with autoflowering — the trait that lets plants flower independently of changes in day length, a characteristic prized by breeders working in northern latitudes and tight cultivation schedules.

Recovering a known result is a standard sanity check for a genotyping platform: it demonstrates that the tool detects real signal rather than noise. The validation population of 321 plants across two breeding lines is modest by crop-genetics standards, where reference studies often run to thousands of accessions, so breeders should treat broader performance claims with that limitation in mind.

The jump in capture efficiency — from 35.8% to 88.5% of targeted sequences recovered — came after subsequent improvements to the platform's design. In practical terms, that efficiency gain determines how much usable data a lab gets per dollar spent on each sample, which is the number that decides whether a platform scales beyond a pilot.

Computer-based testing, rather than additional wet-lab trials, suggested the platform could perform well across diverse cannabis varieties, including those bred specifically for high cannabinoid content. That result is a projection from simulation, not a measured outcome across all variety types, and the study's authors frame it accordingly.

Who built it, and who paid for it?

The research team included scientists affiliated with Cornell University, the USDA, Colorado State University, Lancaster University, Organigram and Agilent Technologies. The presence of a major cannabis producer (Organigram) and an instrument manufacturer (Agilent Technologies) signals commercial interest in the tool, a relevant fact for R&D managers weighing vendor claims in this sector.

Funding came from the Foundation for Food and Agriculture Research and the New York State Department of Agriculture and Markets — public agricultural science money rather than industry sponsorship, which strengthens the case that the performance figures were not shaped by a product marketing agenda.

The researchers have also released the platform's genetic data and design code publicly. For breeding operations with in-house bioinformatics capacity, that openness means the platform can be adopted, audited and modified without licensing negotiations, and it allows independent labs to reproduce the 88.5% capture figure before committing budget.

What changes for breeding programs?

The study positions CannSelect as a low-cost, scalable route to high-quality genetic data. If the efficiency gains hold in commercial populations, breeders could screen seedlings for disease resistance, flowering time and cannabinoid profiles at the DNA level earlier in a cycle, cutting the time and greenhouse space spent raising plants that will be discarded.

The immediate next step, implied by the authors' own framing of the simulation results, is validation across a wider range of varieties — particularly high-cannabinoid lines — under real laboratory conditions.

via themarijuanaherald.com (Source)

Filed under

  • cannselect
  • cannabis-genotyping
  • targeted-genotyping
  • cannabis-breeding
  • plant-genomics
Share this article:

More from Rebecca Stone

Rebecca Stone

Show full bio

Market editor covering regulation, policy and their impact on research and development at Hypothesis Wire.

274 articles

References

  1. Massachusetts Approves Mandatory Lab Retesting in Cannabis Overhaul
  2. Senate Bill Would Lift Hemp Program Funding 30%, Push FDA on Cannabinoid Pain Drugs
  3. EU Moves to Build Continental Infrastructure for Plant Genetic Resources
  4. FDA Proposes First Drug-to-Supplement Path That Could Reach CBD
  5. Jazz Pharmaceuticals Wins Two U.S. Patents Covering CBD-C4 and CBD Derivatives

« Previous articleNext article »